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Abstract
Background: Compensating participants of biomedical research is a common practice. However, its proximity with
ethical concerns of coercion, undue influence, and exploitation, demand that participant compensation be
regulated. The objective of this paper is to discuss the current regulations for compensation of research participants
in Malawi and how they can be improved in relation to ethical concerns of coercion, undue influence, and
exploitation.
Main text: In Malawi, national regulations recommend that research subjects be compensated with a stipend of
US$10 per study visit. However, no guidance is provided on how this figure was determined and how it should be
implemented. While necessary to prevent exploitation, the stipend may expose the very poor to undue influence.
The stipend may also raise the cost of doing research disadvantaging local researchers and may have implications
on studies where income stipend is the intervention under investigation. We recommend that development and
implementation of guidelines of this importance involve interested parties such as the research community and
patient groups.
Conclusion: Compensating human research subjects is important but can also act as a barrier to voluntary
participation and good research efforts. Deliberate measures need to be put in place to ensure fair compensation
of research participants, avoid their exploitation and level the field for locally funded research.
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Background
On 01 November 2017, the Malawi government through
the National Health Sciences Research Committee (NHSR
C), directed that all human subjects research should
provide study participants with US$10 per study visit
as compensation for costs. To our knowledge, Malawi
does not have a comprehensive document which provides
a breakdown of how the new US$10 compensation was
determined or how it should be implemented. In 2018,
Malawian researchers and regulators proposed a standard-
ized approach for implementing the compensation for
research subjects, but this is yet to be adopted by the
NHSRC [1].
Compensation of research participants is a common
and widely acceptable practice [2]. Compensation may
be handed out as refunds for expenses incurred by
participants; for time, effort and inconvenience; injury
or harm associated with research participation or as
incentives to stimulate participants to follow the study
protocol to completion [2]. However, this practice
raises ethical concerns of coercion, undue influence,
and exploitation [3], hence the need for regulation.
In the context of human biomedical research, there
are no universally agreed definitions for coercion or
undue influence; nor is there agreement on how much
compensation constitutes undue influence [3, 4]. Ac-
cording to the Belmont Report, “Coercion occurs when
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an overt threat of harm is intentionally presented by
one person to another in order to obtain compliance.
Undue influence, by contrast, occurs through an offer
of an excessive, unwarranted, inappropriate or im-
proper reward or other overture in order to obtain
compliance. Also, inducements that would ordinarily
be acceptable may become undue influence if the sub-
ject is especially vulnerable” [5]. Coercion and undue
influence are rightfully considered due to their effect
on informed consent [2, 4].
In order to participate in biomedical research, partic-
ipants must voluntarily agree after fully considering all
the risks and benefits of participation. If large enough,
there is concern that compensation may induce poten-
tial participants to participate in research which
conflicts with their deeply held values and beliefs or
overlook certain risks which they would otherwise not
accept, had the ‘compensation’ not been present [4].
This would be a violation of the informed consent
process, which is itself an application of the principle
of autonomy or respect for persons; the emphasis of
which follows a historical record of abuse and mis-
treatment of research participants [5].
Similarly, concerns that compensation may cause
undue influence must be weighed against the risk of
exploitation and the ability of participants to make
informed choices as autonomous agents. While some
scholars argue that participants should enroll in
research studies for altruistic reasons [6], many more
support compensation of participants [3], with some
arguing whether participants are compensated enough
[7]. In addition, evidence suggests that while the
amount of compensation affects willingness to partici-
pate in research, it does not minimize the ability of
individuals to reasonably assess risk of participation in
studies [8–10]. In this paper, we discuss compensation
practices in Malawi. We first take an international per-
spective on compensation guidelines for low resource set-
tings. We review compensation guidelines in Africa using
South Africa as a proxy. Then, we focus on the merits and
drawbacks of current Malawian regulations, propose
changes to these regulations and make recommendations
to improve on current practice.
Main text
International research perspective
Low and middle-income countries (LMICs) especially in
Sub-Saharan Africa have long been fertile ground for re-
search on infectious diseases which are highly prevalent
in these settings [11]. However, the global spread of the
Human Immunodeficiency Virus (HIV) in the 80s and
90s which disproportionately affected these regions [12]
led to a larger increase in the disparate burden of bio-
medical research from wealthy developed countries to
developing nations. Increasingly, the poor and citizens
of low and middle-income countries in Africa, South
America and Asia became subjects of research funded
by stakeholders in North America and Western Europe
[13–16]. To ensure ethical conduct of clinical research
in these low socio-economic groups and regions, inter-
national guidelines were developed to aid researchers
to navigate this new landscape and protect participants
from exploitation and harm [17].
The revised Council for International Organizations
of Medical Sciences (CIOMS) International Ethical
Guidelines for Health-related Research Involving
Humans published in 2016 are the latest in a series of
guidelines published on how ethical principles should
be applied in biomedical research in LMICs [17, 18].
They make a distinction between reimbursement (re-
payment for out-of-pocket expenses incurred) and
compensation. The guidelines state that participants
should be “reasonably reimbursed” for direct research
costs such as transport to and from the study site.
They should also be “reasonably compensated” for in-
convenience and time spent. Monetary compensation
should be proportional to the time spent and calcu-
lated using in-country hourly wage as a reference.
Compensation can also be in the form of goods such
as food packages and services such as healthcare packages
and medical insurance but should never be “meant to
compensate for risk”. There are also guidelines for com-
pensation for persons unable to give consent, compensa-
tion after study withdrawal (including research related
harms incurred during the study) and studies which use
financial incentives as interventions [17].
Compensation and trial incentives for research participants
in Africa
In Africa, there is no uniform approach to compensa-
tion for research subjects across various countries [19].
This reflects different legal and policy environments as
well as cultural differences across the continent. We
will briefly look at practices in South Africa before re-
view and discussion of practices in Malawi.
The South African National Health Act (2003) makes
compliance with guidelines for Good Clinical Practice
(GCP) mandatory [20]. The second edition of the
South African Guidelines for GCP in the conduct of
clinical trials (2006) includes sections on the compen-
sation of trial participants for research related injury
and trial incentives. Incentives, defined as payments or
concessions made to encourage a certain action or be-
havior, are acceptable under these guidelines. Incen-
tives should not be excessive as to make an offer a
participant “cannot refuse”. Participants must be reim-
bursed for all “reasonable costs incurred” during trial
participation. Incentives can be financial, transport or
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food. Information on incentives must be provided to
participants and included in the protocol and in the
case of multicenter trials, differences in compensation
across sites must be explained to the participants.
The guidelines also require sponsors to provide com-
pensation for injury incurred due to participation in
research. This is irrespective of whether the participant
can prove negligence on the part of the sponsor or in-
vestigator. However, the sponsor is under no obligation
to pay compensation where there is “failure of a medi-
cinal product to have its intended effect or to provide
any other benefit” and “injury caused by other licensed
medicinal products…. for…. comparisons with the prod-
uct under trial”. Furthermore, the sponsor may not pay
compensation where there is a failure of placebo to pro-
vide therapeutic benefit and injury due to deviations
from the agreed protocol, a third party or negligence on
the part of the participant [20].
Compensation of research participants in Malawi
The National Health Sciences Research Committee is
one of two research ethics committees (RECs) delegated
by the Government of Malawi to provide research over-
sight and develop guidelines for the conduct of research
in Malawi [21, 22].
On 01 November 2017, the NHSRC notified all in-
vestigators involved in health research on human
subjects “to reimburse all study participants a Malawi
Kwacha equivalent of 10 US $ as stipend to partici-
pants during each scheduled visit to the facilities where
research is taking place” [23]. However, no formal
guidelines were laid out on how this figure was deter-
mined, how this guideline would be implemented nor
the specific purpose for which participants would be
reimbursement. In 2018, researchers and regulators in
Malawi proposed a standardized approach which used
renumeration tables to calculate how much and for
what purpose a participant should be compensated [1].
However, this has not yet been implemented.
Four models for compensation of research participants
are generally recognized: market model, wage-payment
model, reimbursement model and appreciation model
[2, 24]. In the market model, forces of supply and de-
mand determine the amount to be compensated and
payment serves as an incentive for enrollment into the
study or completion of follow up schedule. In the
wage-payment model, participation in research is
treated as a form of unskilled labor with a standardized
wage for time and effort put into the research process.
The wage is commensurate with the minimum wage in
the country. The reimbursement model recognizes that
participants must not incur a cost for participation in
research. Participants are reimbursed for transport,
meals, lodging and it may also take into account lost
wages or economic opportunity for time spent in the
study. In the appreciation model, payment is a reward
or token of thanks for participation in the study [24].
Regarding guidance for compensation of research par-
ticipants in Malawi, it is unclear which, if any, of these
models the guideline to pay $10 stipend falls under.
We support compensation of research participants and
believe that the $10 minimum compensation per study
visit was set to prevent exploitation. While research pro-
vides evidence-based solutions to problems faced by
mankind and can thus be a public good, it provides dir-
ect benefits to sponsors (e.g. pharmaceutical companies)
and researchers. The pharmaceutical industry is worth
billions of dollars and investigators and those they
employ are paid for their work. It is only reasonable and
fair that individuals who participate in research also
receive direct benefits in addition to ancillary care pro-
vided in many research settings, and their communities
have assured access to products post-registration. To do
otherwise would be tantamount to exploitation of these
participants especially in the context of research on the
poor benefiting those that are well off. This benefit
sharing is consistent with the principle of justice. This
sentiment to expect reasonable and fair compensation is
shared by community members [16].
However, to remain ethical, participant compensa-
tion need not be the sole reason for subjecting oneself
to research procedures. In a setting where over 60% of
the population lives on less than $2 per person per
day, the current $10 per study visit, may easily act as
undue influence. Poverty is an insidious barrier to au-
tonomous decision-making, predisposing individuals to
unfair power dynamics [15]. The principle of respect
for persons requires that research participants are
treated as autonomous individuals and those with di-
minished autonomy are protected [5].
The new research participant compensation strategy
is likely to slow rather than nurture locally brewed re-
search. Some researchers, especially the locally funded,
and students, may not have the necessary financial
resources to honor it. This would, in turn, suppress lo-
cally brewed research in favor of the well-funded, often
international work. Although exceptions for payment
of $10 stipend have been made for undergraduate and
postgraduate students, a cohort of local graduate
researchers not undertaking academic study are still
required to adhere to guidelines. For the exempted,
their recruitment efforts may be subject to unfair com-
petition from well-funded studies that are compensat-
ing participants at a higher rate. Research regulation
should nurture and not deter research efforts.
Lastly, the US$10 participant stipend may affect the
interpretation of studies where outcomes are influenced
by social-economic determinants and where financial
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incentives serve as interventions. For example, in a
study to evaluate HIV care delivery models among
adolescents where the primary outcome is retention in
care, the inclusion of the stipend and other incentives
may affect the results of the study by shifting the
social-economic base. Therefore, effects of social eco-
nomic determinants on retention can hardly be realis-
tically measured. This creates a dilemma, particularly
on how to strike a balance between science and ethics
for these types of studies when the social-economic
structure has been altered.
Recommendations
Development of national guidelines on compensation of
participants
Malawi has taken a significant step forward with devel-
opment of regulations for research including address-
ing the important angle of participant compensation.
However, the release of any regulation is incomplete if
not accompanied by instructions for practical imple-
mentation by all relevant users. Clearer definitions of
compensation, reimbursement, and incentives, their
applicability and enforcement are urgently needed. If
researchers, ethics committees, regulatory authorities,
health institutions, and representatives of research par-
ticipants (Community Advisory Boards and patient
groups) are given detailed and clear instructions on
what is expected of them in what circumstances of bio-
medical research, implementation of regulations would
be smoother. We urge the NHRSC, and similar bodies
elsewhere to consider developing such guidelines as
they release new regulations.
Community consultation
Regulation for a collaborative process such as research,
may achieve its goals better if developed collabora-
tively. The current regulation for participant compen-
sation was handed down without any warning or
consultation leading to disjointed implementation and
adherence. We recommend timely consultations with
the research community which, at a minimum, com-
prises of researchers, ethics committees, regulatory au-
thorities, health institutions, and representatives of
research participants (Community Advisory Boards
and patient groups) and communities. Detailed consul-
tations with prospective implementers and subject of
regulation lends the process legitimacy and breathes
success into the final outcome. In this direction, we
welcome the consultative meeting the regulators had
with researchers in 2018 and hope that more sections
of the research community will also be reached out to
and that outcomes of such meetings will be part of an
amended regulation and guideline.
Alternative compensation
It has been proposed previously and we echo this senti-
ment that compensation or payment should not only be
monetary but can also be in the form of goods (e.g. food,
soap, educational materials etc.) and services such as
“ancillary” care provided to participants and their fam-
ilies [2, 24]. This helps prevent monetization of the
researcher-participant relationship but also prevents
awkwardness in situations where financial compensation
may not be the most appropriate method [25, 26]. It
may also provide a reprieve for local researchers who
may not afford monetary but alternative compensation.
However, we are mindful that there may not be a one
size-fits-all kind of compensation and that in some areas,
monetary forms of compensation may be the best way.
We propose adapting mode of compensation to commu-
nity preferences determined through consultative meet-
ings or qualitative studies.
Conclusions
We welcome strides the Malawi government has made
with respect to research regulation and appreciate the set-
ting of minimum amount of money for human research
subject compensation as a means to prevent exploitation.
We are however concerned that the current amount of
US$10 may: a) suppress the often-underfunded local re-
searchers, and b) in some cases, fail to balance off coercion
and undue influence especially being in a population
where most do not make more than $2 per day. We are of
the opinion that regulations development for a collabora-
tive process like research can cover more ground and
become more implementable if it involves the entire
research community. Just like standard operating proce-
dures accompany research protocols, new regulations
ought to be released with clear guidelines showing expec-
tations of all members of the research community which,
at a minimum, comprises of researchers, ethics commit-
tees, regulatory authorities, health institutions, and repre-
sentatives of research participants (Community Advisory
Boards and patient groups) and local communities. We
also recommend a slight departure from the one-size-fits-
all approach for human subject research participant com-
pensation towards a needs-responsive approach that takes
community ideas onboard.
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